<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03495739</url>
  </required_header>
  <id_info>
    <org_study_id>HUG171</org_study_id>
    <nct_id>NCT03495739</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Assess the Safety and Pharmacokinetics of RDG-17012 Capsule and Pradaxa® Capsule in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of RDG-17012(Dabigatran Etexilate Tosylate) With Pradaxa® Capsule(Dabigatran Etexilate Mesylate) in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huons Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huons Co.,Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single-dosing, 2x2 crossover study, the safety and pharmacokinetics
      of RDG-17012 with Pradaxa® in healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve(AUC) last of Total dabigatran and Free dabigatran</measure>
    <time_frame>(Day0)0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12hour, Day 1, Day2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum of concentration(Cmax) of Total dabigatran and Free dabigatran</measure>
    <time_frame>(Day0)0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12hour, Day 1, Day2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve(AUC)inf of Total dabigatran and Free dabigatran</measure>
    <time_frame>(Day0)0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12hour, Day 1, Day2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>RDG-17012® capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RDG-17012 ® capsule(dabigatran etexilate tosylate)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pradaxa® capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pradaxa® capsule(dabigatran etexilate mesylate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RDG-17012 Capsule</intervention_name>
    <description>Dabigatran Etexilate tosylate 150mg</description>
    <arm_group_label>RDG-17012® capsule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran Etexilate Mesylate 150 MG Oral Capsule</intervention_name>
    <description>Dabigatran Etexilate mesylate 150mg</description>
    <arm_group_label>Pradaxa® capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 19 to 45, healthy male subjects(at screening)

          -  Subject without a hereditary problems, chronic disease and morbid symptom

          -  Volunteer who totally understands the progress of this clinical trials, make decision
             by his free will, and signed a consent form to follow the progress

        Exclusion Criteria:

          -  Volunteer who has past or present history of any diseases following below.(liver,
             kidney,digestive system, pulmonary,hematooncology, endocrine, urinary,neurology,mental
             disorder, skeletomuscular, immunology, otolaryngology,cardiovascular)

          -  Exceed 2 times the normal range of AST, ALT, Total Bilirubin at screening test

          -  History of drug abuse, or a positive urine drug screen

          -  Regular alcohol consumption(over 21 units/week, 1unit=10g of pure alcohol) or
             volunteers who cannot abstain from drinking during the study

          -  Any condition that, in the view of the investigator, would interfere with study
             participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Huons</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Seongnam-si</state>
        <zip>13486</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

